These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26755716)

  • 1. Control or overcontrol for covariates?
    Streiner DL
    Evid Based Ment Health; 2016 Feb; 19(1):4-5. PubMed ID: 26755716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements.
    Hernández AV; Steyerberg EW; Habbema JD
    J Clin Epidemiol; 2004 May; 57(5):454-60. PubMed ID: 15196615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covariate adjustment and estimation of mean response in randomised trials.
    Bartlett JW
    Pharm Stat; 2018 Sep; 17(5):648-666. PubMed ID: 29998483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trials with time-to-event outcomes: how much does prespecified covariate adjustment increase power?
    Hernández AV; Eijkemans MJ; Steyerberg EW
    Ann Epidemiol; 2006 Jan; 16(1):41-8. PubMed ID: 16275011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covariate adjustment in randomized controlled trials: General concepts and practical considerations.
    Van Lancker K; Bretz F; Dukes O
    Clin Trials; 2024 Aug; 21(4):399-411. PubMed ID: 38825841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials?
    Karrison T; Kocherginsky M
    Clin Trials; 2018 Apr; 15(2):178-188. PubMed ID: 29502444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals.
    Austin PC; Manca A; Zwarenstein M; Juurlink DN; Stanbrook MB
    J Clin Epidemiol; 2010 Feb; 63(2):142-53. PubMed ID: 19716262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To adjust or not to adjust for baseline when analyzing repeated binary responses? The case of complete data when treatment comparison at study end is of interest.
    Jiang H; Kulkarni PM; Mallinckrodt CH; Shurzinske L; Molenberghs G; Lipkovich I
    Pharm Stat; 2015; 14(3):262-71. PubMed ID: 25866149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covariate adjustments in randomized controlled trials increased study power and reduced biasedness of effect size estimation.
    Lee PH
    J Clin Epidemiol; 2016 Aug; 76():137-46. PubMed ID: 26921693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing the power of the Mann-Whitney test in randomized experiments through flexible covariate adjustment.
    Vermeulen K; Thas O; Vansteelandt S
    Stat Med; 2015 Mar; 34(6):1012-30. PubMed ID: 25475954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies.
    Kahan BC; Jairath V; Doré CJ; Morris TP
    Trials; 2014 Apr; 15():139. PubMed ID: 24755011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Power and sample size calculations for discrete bounded outcome scores.
    Tsonaka R; Rizopoulos D; Lesaffre E
    Stat Med; 2006 Dec; 25(24):4241-52. PubMed ID: 16947202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current issues with covariate adjustment in the analysis of data from randomized controlled trials.
    Alemayehu D
    Am J Ther; 2011; 18(2):153-7. PubMed ID: 19797942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mind the gap: covariate constrained randomisation can protect against substantial power loss in parallel cluster randomised trials.
    Kristunas C; Grayling M; Gray LJ; Hemming K
    BMC Med Res Methodol; 2022 Apr; 22(1):111. PubMed ID: 35413793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covariate adjustment in randomized clinical trials with missing covariate and outcome data.
    Chang CR; Song Y; Li F; Wang R
    Stat Med; 2023 Sep; 42(22):3919-3935. PubMed ID: 37394874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving precision and power in randomized trials with a two-stage study design: Stratification using clustering method.
    Ye X; Lu N; Xu Y
    Pharm Stat; 2023 Mar; 22(2):396-407. PubMed ID: 36504179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous covariate imbalance and conditional power for clinical trial interim analyses.
    Ciolino JD; Martin RH; Zhao W; Jauch EC; Hill MD; Palesch YY
    Contemp Clin Trials; 2014 May; 38(1):9-18. PubMed ID: 24607294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explaining community-level variance in group randomized trials.
    Feng Z; Diehr P; Yasui Y; Evans B; Beresford S; Koepsell TD
    Stat Med; 1999 Mar; 18(5):539-56. PubMed ID: 10209810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using audit information to adjust parameter estimates for data errors in clinical trials.
    Shepherd BE; Shaw PA; Dodd LE
    Clin Trials; 2012 Dec; 9(6):721-9. PubMed ID: 22848072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.